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Abstract 69 
Objective: The Neuropeptide-Y (NP-Y) gene is a strong candidate gene in the pathophysiology of 70 
obesity-linked behavior, and several single-nucleotide polymorphisms of NP-Y have already been 71 
linked to body weight, and appetite. However, the results from current studies remain inconclusive. 72 
The aim of the present study was to test whether a certain functional genetic variant (SNP rs16147) in 73 
the NP-Y promoter gene is associated with leptin and body-fat distribution. 74 
Method: We genotyped and measured the serum leptin levels of the NP-Y rs16147 polymorphism in 75 
1097 Caucasian subjects in the context of a population-based, case-control multicenter study. We 76 
measured weight, height and waist circumference, from which we then calculated body mass index 77 
and waist-hip ratio (WHR).  78 
Results: We found the CT-genotype of the SNP rs16147 to be significantly associated with lower 79 
waist-hip ratios and higher serum leptin levels in women, compared to homozygote gene carriers. No 80 
association between rs16147, WHR and leptin levels was found in men.  81 
Conclusion: Our results provide evidence that the functionally relevant SNP in the NP-Y promoter 82 
gene affects body-fat distribution and leptin plasma concentration in women pointing towards possible 83 
behavioral effects of NPY in obesity. 84 
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INTRODUCTION 100 
Obesity is a major health problem with extensive consequences not only for those if affects but also 101 
for society as a whole [1]. In particular, central obesity – which is measured using waist-to-hip ratio 102 
(WHR) – is associated with increased risk of diabetes, depression, kidney disease, obesity-related 103 
cancers, and death from cardiovascular disease [2-5]. However, the mechanisms and pathways 104 
underlying central obesity and regulation of body-fat distribution are not completely understood. While 105 
the genetic risk factors [6] as well as the environmental factors [7-10] underlying obesity are still 106 
relative poorly understood, a better understanding of the complex interactions between physical, 107 
endocrinological, genetic and molecular phenotypes is needed [11]. Recent evidence suggest that 108 
only around 50 % of the variation between individuals in body weight has a genetic basis, but these 109 
effects are dominated by polygenetic environmental interactions that reflect many genetic influences 110 
affecting spontaneous physical activity, metabolic rate, endocrinological changes, and appetite 111 
behavior [1]. There are a large number of hormones and neuropeptides involved in regulating the 112 
homeostasis of body weight, appetite, and food intake. Current research has shown the leptin and 113 
neuropeptide-Y systems to be two of the most interesting and important regulators of appetite and 114 
energy homeostasis [12,13]. Since leptin, an anorexigenic peptide, is secreted by adipocytes in 115 
proportion to lipid reserves, leptin levels provide feedback about the body’s fat stores [14]. Leptin is 116 
also involved in the long-term regulation of adiposity, and recent research has suggested that leptin 117 
diminishes food intake by signaling satiety in the hypothalamus [14]. In obese persons, a leptin-118 
resistance mechanism affects leptin’s regulatory effect, which explains the positive correlation 119 
observed between leptin levels and body-fat mass [15]. In contrast to leptin, neuropeptide-Y is an 120 
orexigenic neuopeptide, and it promotes food intake and helps reduce energy expenditure [16]. A 121 
recently published study found that changes of plasma levels of Anti-neuropeptide-Y plasma 122 
immunoglobulins are relevant to altered appetite and body weight in patients with depressive disorder 123 
[17]. Findings from a recent study suggest that circulating leptin directly engages NP-Y neurons, thus 124 
regulating body-weight homeostasis [18]. Furthermore, melatonin recently has been found to play a 125 
role in central appetite regulation by modulating the gene transcription of leptin and NP-Y [19]. 126 
Additionally, there is growing evidence that in addition to their roles regulating food intake and energy 127 
expenditure, both peptides (NP-Y and leptin) also closely interact with mesolimbic reward pathways 128 
[20,21]. Since the effects of food intake are self-reinforcing, there has been increased discussion 129 
recently as to whether severe obesity and addiction disorders share any common neuronal circuits 130 
[5,22]. Furthermore, gene variations in both systems (NP-Y and leptin) have been found to be 131 
associated with central obesity as well as numerous psychiatric conditions [14,23-25]. Obesity is to an 132 
essential degree consequence and measure of maladaptive eating behavior. Despite neurobiological 133 
processes controlling food intake, the interaction of genetic, psychological and endocrinological factors 134 
which thus constitute risk factors of weight gain and obesity are complex, but important to investigate 135 
[1]. Analysis of the candidate genes that regulate psychological and endocrinological pathways could 136 
lead to a better understanding of the pathophysiology of central obesity. To this end, we analyzed 137 
whether or not a certain functional genetic variant in the NP-Y-promoter gene (SNP rs16147) is 138 
associated with body-fat distribution and peripheral leptin levels in an ethnically homogenous sample 139 
of healthy white subjects.  140 
 141 
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 143 
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Methods 145 
Data Collection 146 
For the case-control association analysis, we analyzed data from a cohort, investigating the 147 
phenotypes and genetics of nicotine dependence. Of our subjects, 466 were male, 631 were female 148 
(entire sample n=1097), and all were genotyped. Data were collected at seven recruitment centers 149 
located throughout Germany (Depts. of Psychiatry at the Universities of Aachen, Berlin, Bonn, 150 
Duesseldorf, Erlangen, Mainz, and Mannheim) between 2007–2009. All participants were required to 151 
be of German origin and to speak German at a native-speaker level. Only ethnically German subjects 152 
were included. Details on the recruitment, testing procedures, inclusion/exclusion criteria, and 153 
characterization of this multicenter study on nicotine dependence and smoking-related behavior have 154 
been published elsewhere [26,27]. 155 
Prospective subjects’ conformity to inclusion/exclusion criteria was assessed using a medical 156 
examination, a standardized psychiatric interview (SCID-I), questionnaires, drug screenings, alcohol 157 
testing, and CO measurement.  158 
The present study was approved by the ethics committees of all participating centers; subjects were 159 
included in the study only after they had given written, informed consent.  160 
 161 
Measures and testing procedures 162 
The testing sessions were subjected to a strict timetable and included a standardized 600 kcal meal 163 
during a one-hour lunch break taken at noon. The assessments started at 8:30 am and lasted until 164 
4:30 pm for all participants. The absence of psychiatric axis-I co-morbidity was verified using the 165 
Structured Clinical Interview, which is based on DSM-IV criteria (American Psychiatric Association, 166 
2000). Body weight, body-mass index and waist-hip ratio were assessed for all participating subjects 167 
according to standard procedures. BMI was calculated as body weight (kg) divided by the square of 168 
height (m).  169 
 170 
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DNA preparation and genotyping 176 
Genotyping was performed at the Cologne Center for Genomics (CCG) at the University of Cologne. 177 
DNA from fresh frozen EDTA blood was prepared using a Qiagen FlexiGene DNA Kit according to the 178 
manufacturer’s instructions and normalized based on RNase P copy number measurement using the 179 
TaqMan RNase P assay from Applied Biosystems ®, Foster City, Calif., USA. The SNP rs16147, a 180 
functional NP-Y promoter variant, was chosen to cover the functional expression of brain NP-Y. 181 
Genotyping was performed using SNPstream SNP genotyping assays. Genotyping call rates were 182 
99%. All laboratory procedures were carried out blind to case control-status.  183 
 184 
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Hormonal measures 187 
Blood samples were obtained between 2:00 and 4:30 pm by venipuncture, and were then 188 
anticoagulated with sodium EDTA (1 mg/ml whole blood) and immediately cooled on ice. Plasma was 189 
separated by centrifugation with 4000 g, and aliquots were frozen immediately and stored at -80°C 190 
until analysis (max. 6 months). The leptin analyses were performed at the Neurobiological Laboratory 191 
of the Department of Psychiatry at the University Hospital of Hamburg.  192 
To measure leptin, we used a human leptin radioimmunoassay kit (Linco, St. Charlex, MO, USA). The 193 
detection limit was 0.25 ng/ml of plasma; intra- and inter-assay coefficients of variation for 4.9. and 194 
15.7 ng/ml levels were below 8.5%.  195 
 196 
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 198 
Data analysis 199 
Associations between genotype and gender as well as obesity and gender were evaluated using the 200 
chi-squared test. The gender-specific risk of obesity is given in odds ratio and its confidence interval. 201 
Due to the fact all three dependent variables (BMI, WHR and leptin) deviated from a normal 202 
distribution (Kolmogorov-Smirnov test for all three variables: p<0.001), we performed non-parametric, 203 
Mann-Whitney tests in order to compare the influence of the genotype. The genotypes were divided 204 
into two groups: one for homozygotes (CC and TT) and another for heterozygotes (CT). Additionally, 205 
we calculated correlative associations using Pearson correlations (two-tailed). All tested statistics 206 
indicating a p-value of 0.05 or less were considered significant. We tested for deviation from Hardy-207 
Weinberg Equilibrium using a Fisher’s exact test. The data analysis was performed using SPSS 208 
Statistics, version 19.  209 
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Results 213 
Group characteristics 214 
A total of 1097 subjects were genotyped for SNP rs16147. This total sample was primarily female (631 215 
female, 466 male), aged 34.7 ± 12.8 years. SNP rs16147 did not deviate from Hardy-Weinberg 216 
equilibrium (TT=258, 23.5%, CT=561, 51.1%, and CC=278, 25.3%; p=0.469). Genotype distributions 217 
for the study population (women and men) are presented in Table 1. The study population’s 218 
sociodemographic and clinical characteristics have been described in previous papers [27-29]. 219 
For the purposes of this study, obesity was defined as a body-mass index (BMI) of 30 or greater. Of 220 
the participants, n=120 have a BMI greater than 30 (10.9% of the sample); broken down by gender, 221 
n=57 of the women were obese (9%) compared to n=63 of the men (13.5%). Obesity was unequally 222 
distributed between men and women (Chi2=5.578, p=0.018), with men having a higher probability of 223 
being obese compared to woman (OR=1.577, CI 1.08-2.31). 224 
The mean WHR for homozygote allele carriers was 0.834 (± 0.955) compared to 0.819 (± 0.909) for 225 
heterozygote allele carriers. The TT and CC genotypes of rs16147 were significantly associated with 226 
an increased risk of higher waist-hip ratios in comparison to the CT genotype (Mann-Whitney 227 
U=108.760, p=0.008). This association seems to be gender specific, with homozygote (TT and CC; 228 
mean WHR=0.795 ± 0.083) women have significantly higher WHR than heterozygote (CT; mean 229 
WHR=0.773 ± 0.068) women (Mann-Whitney U=33.730, p=0.001). In men this comparison is not 230 
significant (Mann-Whitney U=22.424, p=0.264). However, comparisons of CC and TT alleles did not 231 
show any significant differences (Mann-Whitney U=5.877, p=0.728).  232 
The mean BMI in women was 23.481 (± 4.855), and in men it was 25.301 (± 4.210). This difference 233 
was found to be significant (Mann-Whitney U=187,575, p<0.001). However, the mean BMI’s of 234 
homozygote allele carriers (24.386 ± 4.578) and heterozygote allele carriers (24.170 ± 4.805) did not 235 
differ significantly (Mann-Whitney U=140.927, p=0.212).  236 
The mean leptin level in homozygote allele carriers was 8.798 ± 8.488 ng/ml, compared to 9.669 ± 237 
9.155 ng/ml in heterozygote allele carriers, which indicates significantly higher leptin levels in 238 
heterozygote allele carriers (Mann-Whitney U=152,908, p=0.025). We found the highest leptin levels 239 
in heterozygote women (12.516 ± 10.091 ng/ml), which were higher than both homozygote women 240 
(11.626 ± 8.695 ng/ml), and homozygote men (homozygote: 5.509 ± 6.928 ng/ml; heterozygote: 5.05 ± 241 
4.50725 ng/ml). Peripheral leptin levels were 12.115 (± 9.491) ng/ml in women, compared to 5.296 (± 242 
5.921) ng/ml in men (Mann-Whitney U=55,668, p<0.001).  243 
Finally, we conducted a serie of correlation analyses, the results of which showed leptin to be 244 
significantly associated with BMI (r=0.474, p<0.001). In addition, we found leptin to be positively 245 
correlated with both heart rate (r=0.061, p=0.049) and blood pressure (diastolic: r=0.106, p=0.001; 246 
systolic: r=0.076, p=0.015). We also found BMI to be significantly correlated with WHR (r=0.498, 247 
p<0.001). 248 
We did not observe significant differences between the different alleles of the SNP rs16147 249 
concerning levels of cortisol, ACTH, orexin and cotinin (data not shown). 250 
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Discussion 259 
The novel finding of the present study is that the single nucleotide polymorphism rs16147, located in 260 
the NP-Y gene promoter, is significantly associated with both waist-hip ratio and serum leptin 261 
concentrations. These associations were sex specific, applying only to women. Our main result is not 262 
surprising, since various NP-Y gene variants have recently been found to be associated with obesity 263 
[30]. However, the evidence supporting the association between obesity and polymorphisms of the 264 
NP-Y gene has been inconsistent. In a large study, the functionally relevant NP-Y SNP rs16147 was 265 
not found to be associated with obesity, despite other SNPs covering the NP-Y gene having been 266 
found to be associated with obesity [30]. Our study confirmed this result and also found no association 267 
between BMI and rs16147. However, we did find rs16147 to be associated with the distribution of the 268 
body fat (central obesity). Furthermore, our finding is sex specific. Sexual dimorphism in human body 269 
composition is already well known and has been recently described: Compared to women, men are 270 
taller, they have lower overall fat mass, and their fat distribution, total lean mass, and bone mineral 271 
mass are also different [31]. Previous studies support our main finding, reporting that the genetic 272 
variance for WHR is significantly higher in women than in men [32]. The NP-Y gene thus accounts not 273 
only for BMI, as previous studies had suggested. Our results demonstrate that the NP-Y gene also 274 
accounts for body-fat distribution measured with WHR (an important obesity-related trait), and they 275 
also reveal a gene-by-sex interaction.  276 
In a recently published paper by our group using the same data base, it could be demonstrated that 277 
smokers with a pathological eating behavior show an impaired neuroendocrine regulation of appetite 278 
and are prone to experience higher levels of stress and negative affectivity [26]. Altered psychological 279 
states (e.g. depression, stress) have been repeatedly associated with impaired neurobiological 280 
processes controlling food intake [11,33-35]. An important endocrinological mediator not only 281 
controlling for eating behavior, also acts as an important mediatior in stress reactions and depressed 282 
mood,  is leptin [36]. One finding of our study is that peripheral leptin levels are positively correlated 283 
with BMI, blood pressure, heart rate and waist-hip ratio, a finding which has already been reported 284 
repeatedly [37]. We found significantly higher peripheral leptin levels in women with the CT allele 285 
compared to female CC- and TT-allele carriers (rs16147). Previous studies had already found leptin 286 
levels to be higher in females than males if leptin levels are expressed as a percentage of body 287 
fat.[38,39]. Our result is surprising since most previous studies had found positive associations 288 
between leptin and BMI/WHR [40,41]. However, increased leptin levels have not always been found to 289 
be associated with increased body weight [42,43]. As a restriction, it should be noted that in our study 290 
we assessed leptin levels cross-sectionally, and thus we could not discriminate between acute and 291 
chronic hyperleptinemia, although doing so is important for assessing leptin’s long-term biological 292 
effects.  293 
Taken together, our results suggest that the NP-Y system is involved in body-fat distribution in women. 294 
We found that individuals carrying the risk genotypes TT and CC of rs16147, which have been found 295 
to be associated with altered NP-Y levels in earlier studies [44-46], have both significantly lower 296 
peripheral leptin levels and a higher individual vulnerability to increased waist-hip ratio. These results 297 
were sex specific, implying additional risk factors contributing to the complex phenotype of obesity and 298 
waist-hip ratio. Our study does have some limitations: (a) The study findings are not generalizable to 299 
all people suffering from obesity as the primary goal of the study was not to study obesity but to 300 
investigate tobacco dependence in smokers and non-smokers. (b) We did not investigate whether 301 
rs16147 influences NP-Y and leptin expression directly, indirectly, or whether it acts through other 302 
pathways – a question that should be addressed in future studies. (c) Our study population lacked 303 
ethnic diversity, as the analysis was limited to individuals of German ancestry as a means of avoiding 304 
the effects of population stratification. For this reason, the study findings may not apply to populations 305 
of non-German descent. (d) There are many non-genetic factors that influence waist-hip ratio and 306 
leptin levels, including circadian rhythms, psychological factors, sex, addiction, as well as other 307 
hormones like insulin and cortisol, none of which were taken to account in the present study. However, 308 
the strengths of our analysis is, we found a so far unknown association in the NP-Y gene promoter 309 
that may constitute a genetic risk factor for elevated waist-hip ratio in woman. However, further studies 310 
are needed to replicate our preliminary findings.  311 
To our knowledge, this is the first study showing a gene-by-sex interaction with an association 312 
between rs16147, leptin and waist-hip ratio. However, the pathogenesis of obesity and obesity-313 
related-traits is complex and involves both genetic and environmental factors. Therefore, additional 314 
studies looking at different genes, exact (endo-)phenotypes and environmental factors would be useful 315 
contributions to this field.  316 
 317 
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